Dizal's ZEGFROVY® Shines in Phase 3 Study Defeating Chemotherapy in Lung Cancer Treatment#China#Shanghai#Dizal#EGFR_Mutation#ZEGFROVY
Dizal's ZEGFROVY® Shines in Phase 3 Study Defeating Chemotherapy in Lung Cancer Treatment
Dizal announced groundbreaking results from the WU-KONG28 trial, showcasing ZEGFROVY®'s superiority over chemotherapy in treating lung cancer.
third-news.com
May 29, 2026 at 1:03 PM
Dizal's ZEGFROVY® Shines in Phase 3 Study Defeating Chemotherapy in Lung Cancer Treatment#China#Shanghai#Dizal#EGFR_Mutation#ZEGFROVY
Longest Median Overall Survival Achieved with Libtayo and Chemotherapy for EGFR Exon 20 Insertion Positive Lung Cancer#USA#Seoul#Lung_Cancer#EGFR_Mutation#Libtayo
Longest Median Overall Survival Achieved with Libtayo and Chemotherapy for EGFR Exon 20 Insertion Positive Lung Cancer
A new combination therapy of Libtayo and chemotherapy shows a remarkable median overall survival improvement for patients with EGFR exon 20 insertion positive lung cancer, raising hope for better outcomes.
third-news.com
September 18, 2026 at 8:18 AM
Longest Median Overall Survival Achieved with Libtayo and Chemotherapy for EGFR Exon 20 Insertion Positive Lung Cancer#USA#Seoul#Lung_Cancer#EGFR_Mutation#Libtayo
Johnson & Johnson Receives Approval for Subcutaneous Amivantamab Injection: A Breakthrough for NSCLC Patients#Japan#Tokyo#NSCLC#EGFR_Mutation#Amivantamab
Johnson & Johnson Receives Approval for Subcutaneous Amivantamab Injection: A Breakthrough for NSCLC Patients
Johnson & Johnson's subcutaneous amivantamab injection approval marks a significant milestone in treating EGFR mutation-positive NSCLC, with improved efficacy.
third-news.com
December 22, 2025 at 6:52 AM
Johnson & Johnson Receives Approval for Subcutaneous Amivantamab Injection: A Breakthrough for NSCLC Patients#Japan#Tokyo#NSCLC#EGFR_Mutation#Amivantamab
Lunit and AstraZeneca Unveil Groundbreaking AI for Cancer Genotyping at AACR 2025#South_Korea#Seoul#AstraZeneca#Lunit#EGFR_Mutation
Lunit and AstraZeneca Unveil Groundbreaking AI for Cancer Genotyping at AACR 2025
Lunit will present an innovative AI study predicting EGFR mutations in NSCLC at AACR 2025, showcasing the potential of AI to enhance cancer diagnostics.
third-news.com
March 26, 2025 at 1:27 PM
Lunit and AstraZeneca Unveil Groundbreaking AI for Cancer Genotyping at AACR 2025#South_Korea#Seoul#AstraZeneca#Lunit#EGFR_Mutation